Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038116 · ClinicalTrials.gov registry record · Phase 3
Embryonic Dopamine Cell Implants for Parkinson's Disease
A Phase 3 study of Parkinson Disease, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT00038116 is a Phase 3 study of Parkinson Disease that has completed, run by University of Colorado, Denver. The registered enrollment target is 40 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00038116, a Phase 3 study of Parkinson Disease, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this trial is to determine if patients who received embryonic dopamine cell implant surgery showed significantly greater improvement in their Parkinson's disease than a control group undergoing the placebo treatment, and to determine if the cell implant surgery was more effective in younger or older patients.
Conditions Studied
Interventions
- PROCEDURE embryonic dopamine cell implant surgery
- PROCEDURE placebo
Study Locations (3)
New York
- North Shore University Hospital - Manhasset
- The Movement Disorder Center, Columbia-Presbyterian Hospital - New York
Colorado
- University Hospital, the University of Colorado Health Sciences Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1995-05 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038116
The ClinicalTrials.gov registry entry for NCT00038116 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which embryonic dopamine cell implant surgery is the first listed.
NCT00038116 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT00038116 about?
NCT00038116 is a clinical study titled "Embryonic Dopamine Cell Implants for Parkinson's Disease". The purpose of this trial is to determine if patients who received embryonic dopamine cell implant surgery showed significantly greater improvement in their Parkinson's disease than a control group undergoing the placebo treatment, and to determine if the cell implant surgery was more effective in y...
What is the current status of trial NCT00038116?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 1995-05. Estimated completion is 2009-08.
What conditions does trial NCT00038116 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT00038116?
The interventions under investigation include: embryonic dopamine cell implant surgery (PROCEDURE), placebo (PROCEDURE).
Who is sponsoring clinical trial NCT00038116?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00038116 being conducted?
This trial has 3 study locations across Colorado, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
RECRUITING · Phase 3
-
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
RECRUITING · Phase 3
-
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
-
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
COMPLETED · Phase 3
-
Flexible-Dose Trial in Early Parkinson's Disease (PD)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.